Restoring Study 329: efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence

Last modified: May 16, 2017

This article is part of the RIAT initiative (Restoring Invisible and Abandoned Trials) and aims to restore the misreported trial that is known as Study 329, funded by SmithKline Beecham (subsequently GlaxoSmithKline). In contrary to the conclusions stated in the original article, these authors found neither clinically relevant nor statistically significant differences in the primary and secondary outcomes between placebo and the drugs under investigation (paroxetine and imipramine). However, clinically relevant increases in harms were found!

Read more about Study 329 and the BMJ feature about the resistance to action on the initial discovery of misreporting of this trial.

 

Title: Restoring Study 329: efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence
Authors: Le Noury J, Nardo JM, Healy D, Jureidin J, Raven M, Tufanaru C, Abi-Jaoude E
doi: 10.1136/bmj.h4320 (2015)

NRIN devotes a great deal of attention to the website’s content and would greatly appreciate your suggestions of documents or links you believe to belong on this website.

This selection is an incomplete convenience sample, and does not reflect NRIN’s vision or opinion. Including an item does not necessarily mean that we agree with the authors nor does it imply we think unmentioned items are of poorer quality.

Please report any suggestions, inaccuracies or nonfunctioning hyperlinks etc. that you discover. Thanks in advance!

Contact
Icon